Review anchor
Receptor-type tyrosine-protein phosphatase C
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Receptor-type tyrosine-protein phosphatase C
CHEMBL3243
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Receptor-type tyrosine-protein phosphatase C as ChEMBL target CHEMBL3243, mapped to UniProt P08575. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3243
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P08575
Receptor-type tyrosine-protein phosphatase C
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Receptor-type tyrosine-protein phosphatase C matters
Receptor-type tyrosine-protein phosphatase C is reviewed as Receptor-type tyrosine-protein phosphatase C (UniProt P08575); Receptor-type tyrosine-protein phosphatase C shows clinical signal disease relevance led by acute lymphoblastic leukemia. 4 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 1331 compounds, and 109 assays, with lead potency reaching pChEMBL 6.8.
Protein context
Receptor-type tyrosine-protein phosphatase C
Receptor-type tyrosine-protein phosphatase C Sequence length is 1306 aa.
Review this target as Receptor-type tyrosine-protein phosphatase C, mapped to UniProt P08575. Sequence length is 1306 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P08575
Protein
Disease context
acute lymphoblastic leukemia
Receptor-type tyrosine-protein phosphatase C shows clinical signal disease relevance led by acute lymphoblastic leukemia. 4 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include AHN-12.
Start review with acute lymphoblastic leukemia because it currently carries clinical signal support. Linked drugs include AHN-12. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 1331 compounds, and 109 assays for this target. The dominant activity type is IC50. CHEMBL200117 is the current potency anchor at pChEMBL 6.8.
Use CHEMBL200117 as the tractability anchor when discussing potency (pChEMBL 6.8).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 6.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Receptor-type tyrosine-protein phosphatase C matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08575, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why acute lymphoblastic leukemia is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1331
Total Compounds
109
Total Assays
0
Approved Drugs
IC50: 1229.0, KI: 876.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL200117
|
6.8 | IC50 | — |
|
|
No preferred name
CHEMBL51314
|
6.7 | IC50 | — |
|
|
No preferred name
CHEMBL515797
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL89067
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL51776
|
6.5 | IC50 | — |
Source Header